How to Promote a Randomized Controlled Trial Without Spin
A practical guide to sharing the results of a randomized controlled trial so that posts, press releases and talks say what the trial found. It covers what spin looks like, what to keep next to the result, a worked example and a checklist.

Your trial paper is out. Years of recruitment, follow-up and analysis now sit behind one sentence in the abstract, and that sentence is about to be copied into a press release, a conference slide, a tweet and a hospital newsletter.
Every one of those copies will be shorter than the paper, and each shortening is a chance for the result to grow. Promoting a randomized controlled trial well means making sure the version people remember is the one your data support.
Why Trials Are Easy to Overstate
Trials answer a sharp question, so their results read like verdicts. Readers and journalists want to know whether the treatment works. Anything that sounds like a yes travels fast.
Researchers have a name for the drift: spin. In a 2012 PLOS Medicine cohort study, Yavchitz and colleagues defined it as specific reporting strategies, intentional or unintentional, that emphasize the beneficial effect of the experimental treatment. They looked at 70 press releases for two-arm, parallel-group trials indexed in EurekAlert! between December 2009 and March 2010, then at the articles and news stories that went with them.
Spin was present in 40% of the abstract conclusions and 47% of the press releases. Of the 41 trials with news coverage, 21 (51%) were reported with spin, mostly of the same type as in the press release and abstract. When assessors read only the press release, they overestimated the benefit of the treatment for 27% of trials compared with reading the full article.
The finding that matters most for you as an author: of the factors the authors tested, including journal type, funding source and sample size, the only one associated with spin in the press release was spin in the article's own abstract conclusion (relative risk 5.6). Spin in the press release tracked spin in the abstract. So the most effective promotion work starts with your own conclusion sentence.
What Spin Looks Like in Practice
The same PLOS Medicine study used a classification of spin that is worth checking your drafts against. It includes:
- A focus on statistically significant results other than the primary outcome comparison: within-group changes, secondary outcomes, subgroup analyses or a modified analysis population.
- Reading a statistically nonsignificant primary outcome as showing that two treatments are equivalent or comparably effective.
- An inadequate claim of safety, or other emphasis on the beneficial effect of the treatment.
None of these requires saying anything false. A true sentence about a secondary outcome, placed where the primary result should be, can still lead readers to the wrong answer. If your primary outcome was not significant, the guide on communicating null results covers how to say so plainly.
What to Keep Next to the Result
The CONSORT group has already worked out the minimum a reader needs. CONSORT for Abstracts exists because, in its authors' words, readers often base their assessment of a trial solely on the information in the abstract. That makes it a good template for any short format, including posts and slides. The table pairs each part of a short summary with what should stay attached to it.
| Part of your post or slide | What should travel with it | Source |
|---|---|---|
| The headline result | The primary outcome, a result for each group, the effect size and its precision (a confidence interval) | CONSORT for Abstracts |
| A percentage reduction | For a yes or no outcome, both the relative and the absolute effect | CONSORT 2010, sub-item 17b |
| "The treatment is safe" | The important adverse events, or an explicit statement that none occurred | CONSORT for Abstracts |
| Who it applies to | Eligibility criteria and the setting where the data were collected | CONSORT for Abstracts |
| A result from a trial stopped early | The reason it stopped; estimates from trials stopped early for apparent benefit are more likely to be exaggerated | CONSORT for Abstracts |
| A link for readers who want more | Trial registration number and register name, plus the source of funding | CONSORT for Abstracts and the open science section of CONSORT 2025 |
Two of those rows deserve a closer look.
Relative and absolute effects together
The CONSORT 2010 statement added a sub-item on outcomes and estimation saying that, for binary outcomes, presentation of both relative and absolute effect sizes is recommended, for clinical interpretability. A relative reduction tells readers how much the risk changed in proportion; the absolute difference tells them how many people out of every hundred were affected. Promotion copy tends to keep the first and drop the second, because it sounds bigger. Keep both.
Harms and conclusions
CONSORT for Abstracts asks authors to describe important adverse effects and, if none occurred, to say so explicitly. It also asks that conclusions be consistent with the results reported, avoid over-generalisation and balance benefits and harms, noting where further studies are needed before the results are used in clinical settings. That is a good test for every promotional sentence: would it still be true if it appeared in your abstract?
What Changed in CONSORT 2025
If you are promoting a recent trial, your paper may already follow the CONSORT 2025 statement, published simultaneously in The BMJ, JAMA, The Lancet, Nature Medicine and PLOS Medicine. It is a 30-item checklist with a new open science section that groups trial registration, where the protocol and statistical analysis plan can be accessed, sharing of de-identified participant data, and funding and conflicts of interest. It also added an item on how harms and other unintended effects were assessed.
That open science section is useful for promotion. A reader who doubts your headline can check the registered primary outcome, the analysis plan and, where you share them, the data. Pointing to those resources in a post, or on the page where your paper lives, shows you are confident in the result as reported.
A Worked Example
Say, as a hypothetical, that you ran a trial of a structured exercise program for older adults after hip surgery. The primary outcome was a fall within 12 months: 12% of the usual-care group fell, against 9% of the exercise group. A secondary outcome, walking speed, improved strongly, the confidence interval for the fall result was wide, and no serious adverse events were linked to the program.
- Spun post: "Exercise cuts falls by 25% after hip surgery and dramatically improves mobility. A safe, simple fix." It gives only the relative reduction, promotes a secondary outcome to a headline, claims safety without mentioning adverse events, and drops the uncertainty.
- Better post: "In our randomized trial of older adults after hip surgery, 9% of the exercise group had a fall within 12 months, compared with 12% with usual care: a 25% relative reduction, or 3 fewer people per 100 having a fall, with a wide confidence interval. Walking speed, a secondary outcome, also improved. No serious adverse events were linked to the program. Full results are in the paper, and the trial registration is [register name and number]."
The second post keeps the relative and absolute numbers, signals uncertainty, reports harms, keeps the secondary outcome in its place and shows readers where to check. It is the version a journalist or clinician can rely on. If you plan to reach patients as well, the guide on sharing clinical research with patients covers that audience, and pitching your research to journalists covers the press.
A Checklist Before You Share
- Reread your abstract conclusion and check it against the primary outcome before you write anything else.
- Lead with the primary outcome, giving a result for each group.
- Give both the relative and the absolute effect for any yes or no outcome.
- Say how certain the estimate is, in plain words or with the confidence interval.
- Mention important harms, or say that none occurred.
- Label secondary and subgroup results as what they are.
- Read the press release draft against the paper, line by line, before you approve it.
- Include the trial registration number and link the paper in every post.
Where Amplify Fits
The hard part of promoting a trial is keeping the primary outcome, the uncertainty and the harms attached to the headline in every format people actually see. Amplify turns the PDF you upload into a video abstract (16:9, about 3 minutes), a vertical short (9:16, 45 to 60 seconds), an audio brief and a one-page print-ready infographic. They are generated from your paper and nothing else, with no open-web filler, and every artifact carries the title, the authors and a link back to the paper of record.
Each format arrives as three variants you can edit line by line or regenerate, so you can make sure the absolute numbers and the caveats sit next to the result. A subject-matter reviewer reads every draft before it can leave your workspace, every claim is traced to a page in the PDF, and nothing publishes until you approve it. If you share a video abstract with a journal, check its specifications and AI policy first, and ask the editor if you are unsure.
The embeddable widget puts every format beside the paper on your faculty profile, lab site or trial page, where readers can read, listen and chat with the paper without leaving the page. Analytics show reads, listens, questions asked, languages and which format moved people, which is useful for grant reports and broader-impact sections.
A trial result will be retold many times by people who never open the paper. Make the first, shortest version accurate, and the retellings have something solid to copy.
Quick answers
What is spin in the reporting of a randomized controlled trial?
Spin is reporting, intentional or not, that emphasizes the beneficial effect of the experimental treatment. Yavchitz and colleagues counted things like a focus on statistically significant secondary outcomes, subgroups or within-group changes, and reading a nonsignificant primary outcome as proof that two treatments are equivalent, as forms of spin.
Do press releases about clinical trials exaggerate the results?
Often: a 2012 PLOS Medicine cohort study found spin in nearly half of press releases about two-arm trials. Across 70 press releases, spin appeared in 40% of abstract conclusions and 47% of press releases, and of the factors the authors tested, spin in the abstract conclusion was the only one associated with spin in the press release.
Should I report relative or absolute risk when I share trial results?
Give both for a yes or no outcome. The CONSORT 2010 statement added the recommendation that, for binary outcomes, both relative and absolute effect sizes be presented. A relative reduction on its own can sound large while the absolute difference is a few people per hundred, so readers need both numbers.
What should a social media post about my trial include?
Keep the essentials that CONSORT for Abstracts lists: who took part and where, the primary outcome result for each group with its uncertainty, important harms, and the trial registration number. Then link the paper so anyone who wants the full method and results is one click away.



